Kevin Kawchak

Patient Robot Advocacy: A Phase 1, First-in-Human, PDAC Clinical Trial Protocol of a LLM-Directed Robotic Whipple with Daraxonrasib (RMC-6236)

The parent clinical protocol opens with a Statement of Compliance addressed to the Food and Drug Administration, the Institutional Review Board, and the sponsor. That statement is necessary, it is correct, and it is not addressed to the person whose abdomen will be opened. It tel...